Related Experiment Videos
A functional test identifies dopamine agonists selective for D3 versus D2 receptors
F Sautel1, N Griffon, D Lévesque
1Unité de Neurobiologie et Pharmacologie, Centre Paul Broca de l'INSERM, Paris, France.
Neuroreport
|January 26, 1995
Summary
Dopamine agonists show varying potency at D2 and D3 receptors, with some compounds exhibiting functional selectivity. This selectivity is crucial for understanding and treating motor dysfunctions.
Area of Science:
- Pharmacology
- Neuroscience
- Molecular Biology
Background:
- Dopamine receptors, specifically D2 and D3, are critical targets for neurological drug development.
- Understanding the functional selectivity of dopamine agonists is essential for optimizing therapeutic outcomes.
Purpose of the Study:
- To determine the functional potency and selectivity of various dopamine agonists at human D2 and D3 receptors.
- To compare functional selectivity with binding selectivity for a series of dopamine agonists.
Main Methods:
- Utilized transfected cell lines expressing human D2 or D3 receptors.
- Measured mitogenesis via [3H]thymidine incorporation to assess functional potency.
- Evaluated a series of dopamine agonists, including (+)7-OH-DPAT, pramipexole, quinerolane, PD 128,907, and bromocriptine.
Main Results:
- Functional selectivity of agonists differed significantly from their binding selectivity.
- D3 receptor-selective compounds in binding studies showed higher potency at D3 vs. D2 receptors functionally (7-54 fold).
- Bromocriptine demonstrated a 10-fold functional selectivity for the D2 receptor.
Conclusions:
- The D3 receptor plays a role in motor inhibition, as suggested by D3-selective agonist actions.
- Functional selectivity data should inform the development of dopamine agonists for treating motor dysfunctions.